By
Jaclyn Jaeger2021-07-22T16:22:00
The Federal Trade Commission voted to rescind a 1995 policy statement that allowed certain firms taking part in a merger to skirt prior approval requirements.
2021-10-26T19:52:00Z By Kyle Brasseur
The Federal Trade Commission proposed 10-year acquisition restrictions on dialysis service provider DaVita under the agency’s newly reinstated “prior approval” policy aimed at curbing anticompetitive mergers.
2021-09-09T19:00:00Z By Aaron Nicodemus
The Federal Trade Commission, led by new chair Lina Khan, might withdraw its vertical merger guidelines finalized only last year at an upcoming open commission meeting.
2021-07-12T13:21:00Z By Kyle Brasseur
The Federal Trade Commission under new Chair Lina Khan is wasting no time in restoring its power to reshape rulemaking and enforcement, but doing so without proper time for public input is an early cause for concern.
2025-12-10T15:30:00Z By Neil Hodge
For the past decade, Europe has led in creating strong but flexible rules for data use and safe AI development. The EU’s new plans to simplify key data privacy and AI governance measures have received a mixed response.
2025-12-05T19:25:00Z By Oscar Gonzalez
The U.S. Securities and Exchange Commission’s (SEC) Division of Examinations released its 2026 examination priorities, which give companies a roadmap of areas of heightened risk and regulatory focus for next year.
2025-12-04T22:15:00Z By Ruth Prickett
Regulation is a matter of life and death in the pharmaceutical industry. Rules to combat practices that can kill have been in force for decades, but tech developments are rapidly creating new risks and focusing lawmakers’ attention on areas where some compliance teams may lack experience.
Site powered by Webvision Cloud